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502 - Emerging infections in neurological diseases
IMossl Transmissible spongiform encephalopathies (TSE) in
animals
J. Brugere-Picoux, H. Brugere
National Veterinary School ofAlfort, Maisons-Alfort, Frana
Prior 1985 naturally TSEs have been recognised in five animal species:
scrapie in sheep and in goat, transmissible mink encephalopathy, chronic
wasting disease in deer and elk.
Since 1985, TSEs have been reported in cattle, in domestic cats and in a
variety of other species of wild animals (cats and ruminants) maintained in
zoos and wild parks in Great Britain.
Scrapie is the prototype ofthe group ofthese TSEs and was not considered
as dangerous for man giving rise to the concept of the species barrier. At the
opposite, the bovine agent appeared to be able to cross numerous species
barriers including man. These facts justified numerous measures taken
progressively in all countries were the disease was recognised (sporadic or
enzootic form) especially after the crisis of march 1996.
Clinical diagnosis ofbovine spongiform encephalopathy (BSE) is difficult
and it is impossible to detect asymptomatic infected animals in the herd.
Confirmation of a clinical suspicion can be obtained with laboratory
examination after the death of the animal. Improvement of the epidemio-
logical survey with the mean of tests in the slaughterhouses lose an increased
safety for the consumer. These tests will be extended to all groups ofanimals
at risk (found dead, emergency slaughter). An experience ofthis method was
first made in Switzerland. The last problem is the hypothesis ofinfection of
sheep with the BSE agent.
IMoS71 lorna disease virus infections are involved in mood
disorders of man and behavioural diseases of animals
L. Bode', H. Ludwig2
'Robert Koch-Institute; zFree University oflkrlin, Berlin, Germany
Objectives: Prevalence of viral markers, isolates, and therapeutic
approaches, supporting a Link ofBornavirus (BDV) with human depression
analogously to animal Borna disease.
Methods: Detection methods are antibodies in serum and antigens and
nucleic acid in leucocytes, the isolation of infectious virus from positive
leucocytes, in vitro studies of antiviral compounds, and point prevalence as
well as longitudinal follow-ups ofdepressed patients and diseased animals.
Results: BDV, .ilIl ululful; cllvdupcd, negative and si..ngk-stralldl:d RNA
virus of the new family Bornaviridae, is an evolutionary old virus infecting
farm animals, pets (e.g. horses, sheep, cattle, cats), and man. Primary target
cells are neurons ofthe limbic system, but also other cells ofthe brain and the
blood, establishing a persistent non - cytopathogenic infection which
alternates between "latent" and activated states. Possibly, viral components
disturb the balance ofthe neurotransmitter network. In infected animals, e.g.
horses, a relapsing mainly apathetic syndrome has frequently been observed.
In humans, an association with recurrent mood disorders, but also other
diseases of the limbic system, is internationally under debate. Evidence came
from frequent findings of serum antibodies, viral components in blood
leucocytes, from proteins in cerebrospinal fluid of patients with acute
depressive illness, and from a few human Bornaviruses which could have
been isolated so far, in Germany and japan. Despite low genetic divergence,
there are significant biological differences between natural and laboratory
BDV strains (e.g. drug sensitiviry or resistance).
Condusions: BDV is an old virus which is now being recognised as potential
hazard for human mental health.
IMossl West Nile virus infection: A reemerging fatal
arbovirosis
Vincent Deubel
Departmrnt of Virology, Institut Pasteur, Paris, France
Objectives: West Nile virus (WNV) is an arthropod-borne virus of the
family Flaviviridae. WNV is endemic in all Africa, Middle East and Asia. It
circulates periodically in southern and southeastern Europe and has recently
been introduced in the USA. Whether local transmission cycles or repeated
viral introductions from other enzootic areas by migratory birds prevail in
European countries remains unknown.
Methods: Because WNV has a wide geographical distribution, regional
variations among strains of WNV have been investigated on genetic,
phenotypic and epidemiologic bases.
Results: Phylogenetic trees resulting from analyses of sequences for a
portion of the E genc including 40 WN virus strains showed that viruses
segregated in two lineages. Lineage I includes isolates from Africa and all
strains from Europe, Israel and the USA. Lineage II is composed only of
strains isolated in Africa. Thus. a combination of introduction ofWNV by
chronically infected birds from sub-Saharan Africa to southern Europe and
of virus persistence in disease-endemic foci may occur.
Under experimental infection in rodents. WNV can invade the central
nervous system (CNS) via several routes. Inflammatory changes in the CNS
ofinfected mice vary depending on the host and the virus strain. In animals
which succumb to a rapid infection there is a reduced inflammatory effect in
the CNS, due to the lack of time for changes to occur. Immunohistochem-
istry and electron microscopy studi~ reveal extensive replication and
cytopathology occurring in neurons.
Conclusion: Our study underlin~ the role ofbirds and possibly mosquitoes
and humans in the dissemination ofWNV.
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IMoS10I Acute and chronic HBV Infection in transgenic mice
model
M. Chen I, M. Sallberg l , A. Birkett2, j. jones2, J. Hughes2, D. Milichz
IKarolinska Institute, Stockholm, Sweden; zImmune Complex Corporation, San
Diego, CA, United States
To better understand T cell activation and T cell tolerance induction by the
nucleoprotein antigens of HBV, several lineages of HBc/HBeAg-specific
CD4 + TCR transgenic (Tg) mice were produced. The TCR genes were
derived from T cell hybridomas produced from either wild-type mice
immunized with HBeAg or from HBeAg-Tg mice. The CD4+ T cells
present in the TCR-Tg lineages derived from wild-type mice were never
exposed to the HBc/HBeAgs, are of relatively high affinity and represent
naive populations similar to an HBc/HBeAg-specific repertoire during an
acute infection. In contrast, the CD4 + T cells present in the TCR mice
derived from HBeAg-Tg mice are HBc/HBeAg-specific populations which
were selected in the presence of circulating HBeAg, are of relatively low
affinity and may serve as a model for the CD4 + repertoire during chronic
infections.
The acute-like TCR-Tg lineages differ markedly from the chronic-like
TCR-Tg lineages with respect to the (1) affiniry and kinetics of T cell
activation; (2) preferential recognition of the HBc and HBe antigens; (3) in
vitro and i,1 vivo immune responsiveness; (4) Thl/Th2 subset differentiation;
(5) clonal deletion as analyzed in (TCR-Tg x HBc/HBeAg-Tg) "double
Tg" mice; and most importantly (6) the kinetics and severity ofliver injury
occurring after adoptive transfcr into HBc and/or HBeAg-Tg recipients.
The TCR-Tg and TCR x HBc/HBeAg-double Tg systems are providing
unique insights into the complex interactions berween HBV and the host
immune response.
IMoS111 Treatment of hepatitis Cvirus Infection
O. Weiland
Division of Infectious Diseases, Karolinska Institutet, Huddinge University
Hospital, Huddinge, Sweden
Treatment outcome for patients with chronic hepatitis C virus (HCV)
infection has improved substantially during recent years with the develop-
ment oflFN and ribavirin combination therapy.
Combination therapy with IFN-alfa 3 MU t.i.w. plus ribavirin 1000-
1200 mg daily in two divided doses for 6-12 months significantly improves
the biochemical and virological sustained response (SR) rates 2-3 times as
compared to IFN monotherapy given during 12 months. Hence, combina-
tion therapy has become standard therapy both for for naIve and relapse
patients. For genotype 2 and 3 patients 6 months combination therapy is
sufficient whereas genotype 1 patients with high baseline viral load (> 3
million copies/rn1 serum) will need 48 weeks treatment. For the latter group
treatment is still not satisfactory since only 30% will achieve virological SR.
For genorype 2 and 3 patients nearly 70% virological SR rates can be
achieved with 6 months combination therapy provided cirrhosis is not
established. Patients with cirrhosis rcspond less well.
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Combination therapy, however, is superior and better tolerated than IFN
alone also for patients with cirrhosis.
Recently pegylated (Peg) IFN and consensus IFN have been developed
offering higher sustained response rates than ordinary IFN. In particular Peg
IFN, which has a prolonged halflife and offers sustained serum IFN levels for
one week, has been promising. Peg IFN given once a week, in practice
induction dosing, offers a more rapid c1earence ofHCV RNA from serum.
Virological SR rates with Pcg IFN accordingly have been doubled as
compared to those achieved with recombinant IFN given t.i.w. Ongoing
studies and pilot studies indicates that Peg IFN in combination with ribavirin
will improve virological SR rates to more than 50% also for patients with
the unfavourable genotype 1.
IMoS121 Viral hepatitis B: New approaches to management
S. W. Schalm
Dept. ofHepatology & Castroetlterology, Erasmus University Hospital,
Rotterdam, Netherlands
Most carriers of HBsAg have no indication for antiviral therapy at present.
Current antiviral therapies are effective in inducing a sustained virological
response in a small proportion ofpatients in need. In view ofthis. other goals
of therapy, in particular that of a sustained biochemical response with
prolonged therapy are of interest.
For hepatitis B therapy with alpha interferon is available. Results are often
suboptimal due to - according to a recent Eurohep trial- a too short duration
of therapy in potentially responding patients. In HBeAg-negative chronic
hepatitis interferon therapy for 1 year or longer is associated with a lower
incidence ofrelapse than a six-month course and a higher sustained response
rate. In addition, there is now the option of lamivudine monotherapy that
results in suppression of serum HBV DNA, normalization of serum
transaminases (ALT) and improvement in inflammatory activity in the
liver biopsy in 60-70% ofpatients as long as therapy is continued. However,
the emergence of drug resistant viral strains is a particular problem both for
HBeAg-postive and negative chronic hepatitis B.
New anti-HBV nucleoside analogues arc undergoing clinical testing.
Famciclovir has shown minimal anti-HBV activity and interest in the
drug as monotherapy is now fading. Two other guanidine derivatives
drugs (Iobucavir and entecavir) have stronger virus-suppressive potential;
development of lobucavir has been stopped because of longterm carcino-
genicity. A competitive inhihitor of deoxyadenosine (adefovir) is active
against wildtype and lamivudine- resistant hepatitis B virus; its development
may be hampered by renal toxicity. Future effective therapy most likely will
include a (specific?) immunostimulant. Currently combination therapy of
interferon and lamivudine for a year is being tested for improved efficacy and
diminished incidence of resistance.
IMoS131 Elimination of hepatitis Bvirus infection through
vaccination: project. program. problems. prognosis
R. Steffen
Division ofEpidemiology and PrevelJlion of Communicable Diseases, Institute
for Social and PrevelJlive Medicine, University ofZurich, Zurich, Switzerland
Worldwide, hepatitis B virus (HBV) infection is responsible for over 1
million deaths each year and ranks 25th with respect to world wide burden of
disease. In 1992 the World Health Assembly of the WHO recommended
that hepatitis B vaccine be integrated into national immunization programs
in all countries by 1997. As of 1999, 110 countries have a national policy for
routine hepatitis B immunization, and 6 additional countries have a policy
fot immunizing groups at increased risk for HBV infection. All industria-
lized countries except few in Northwestern Europe and Japan routinely
immunize children with hepatitis B vaccine, as do many countries in the
developing world. In many less developed countries financial shortcomings
and weak immunization infrastructures have complicated the addition of
hepatitis B vaccine to their immunization schedules. Routine infant immu-
nization programs are still needed in sub-Saharan Africa, the Indian
subcontinent, and the Newly Independent States. In France, concerns
about possible vaccine side effects have resulted in decreased compliance
with the vaccination despite the fact that, epidemiologic studies have shown
no association between the vaccine and these side effects. With a vaccine
efficacy of about 95%, routine hepatitis B vaccination of all children would
mh<t:mtially reduce HBV-related morbidity and mortality worldwide.
Elimination is a potential target in the long-term only dul.' to thl.' long-
term sustainability of the human reservoir. It is questionable whether
eradication may be achieved.
505 - Travel medicine
IMoS181 Travel medicine: New vaccines for old diseases
B. Genton
Swiss Tropuallnstitute, Basel; Medical University Politlinic, Lausanne,
Switzerland
With the enormous development of molecular biology and genetics, old
vaccines consisting of whole killed or live-attenuated organisms are pro-
gressively replaced by vaccines made of highly purified recombinant
proteins, synthetic peptidcs or even naked DNA. These compounds arc
definitely less reactogenic, but have the disadvantage of inducing lower
immune responses. To compensate for that, a lot of effort is being made to
develop new adjuvants, immunomodulators, carriers and delivery systems,
as well as appropriate mode of administtation and immunization schedules.
Several new vaccines fot travellers have been commercialised recently,
including for example the combined hepatitis A & B vaccine, a new
injectable typhoid vaccine and an oral cholera vaccine. A number of
others are cuttent!y in Phase III efficacy trials including vaccines against
travellers' diarrhoea, malaria and hepatitis E.
Although the tendency is to develop combined vaccines, the number of
injections and the cost becomes a real concern for both the travel medicine
practitioners and the clients. More precise risk-benefit and costeffectiveness
evaluations are needed in order to propose the right vaccinations for the right
trip. Also travellers must be remembered that vaccines are only an adjunct to
the overall health care. and not an alternative to preventive behaviour.
~om STDs resistance patterns and standard treatments
E. Nagy
Department ofClinical Microbiology, University of Szeged, Hungary
Travelling (particularly abroad) involves health risks as compared to the
hazards of everyday travel-free life. The risks include the acquisition of
infectious diseases not present in the home country (e.g. various tropical
diseases), gastroenteritis (the most frequent case) and sexually transmitted
diseases (STDs) Short-time migration often leads to increased sexual risk.-
taking with casual partners. Mobile prostitution has become an increasing
epidemiological factot for the spread of STDs, including high-level anti-
biotic-resistant pathogens.
Recent social-economic changes have resulted in dramatic increases in the
prevalence of syphilis in almost all eastern and central European countries
(e.g. the increase of syphilis in Russia in 1996 was 61 times as compared to
1989, up to 265 cases{l00 000 population). Because of the poot economic
situation, sensitive laboratory screening and diagnostic methods are used to
only a limited extent for the detection of C. trachomatis and N. gono"hoeae
infections. Following the emergence of penicillin, tetracyclin and spectino-
mycin-resistant N. gonorrhoeae in different parts of the world, CDC has
recommended that 3rd-generation cephalosporins and ftuoroquinolones be
used to treat patients with uncomplicated gonorrhoea. During recent years,
no expressed resistance to the 3rd-generation cephalosporins has been
observed, but a clinically significant increase of resistance to ciproftoxacin
has emerged. Typing methods help us to follow the spread of multiply
resistant N. gono"hoeae in both developed and undeveloped countries. New
effective treatment recommendations are needed for countries with different
epidemiological situations involving STDs.
IMoS21 I Diarrhoea in travellers - Prevention .. treatment
H. Pichler
4th Medical Department, Kaiser Franz Hosej Hospital, Vienna, Austria
20-50% ofthe approximately 20 million people who travel from temperate
industrialized countries to tropical countries each year acquire Traveller's
diarrhoea (TO). TD starts most ftequently between the 3rd and the 4th day
after arrival in a tropical area. The illness is generally selftimited, lasting 1-5
days. Bacterial enteric pathogens cause more than 75% of cases of TO. The
causative organisms vary considerably with location. In all areas enterotoxi-
genic E. coli (ETEC) is the most common isolate from persons with the
classic secretory traveller's diarrhoea syndrome ranging from approximately
SU% in Latin America to 15%, in Asia. Shigella, Salmonella and Campylo-
